Securities Fraud Investigation Into National Grid plc (NGG) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
IF YOU ARE AN INVESTOR WHO LOST MONEY ON NATIONAL GRID PLC (NGG), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On July 1, 2025, the National Energy System Operator in the UK published a report stating that a fire on March 20, 2025, that resulted in Heathrow Airport shutting down, had been caused by a known fault at an electrical substation owned by National Grid, which had been aware of the problem since 2018 but failed to fix it.
On this news, National Grid's stock price fell $3.77, or 5.1%, to close at $70.61 per share on July 2, 2025, thereby injuring investors.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice
Persons with non-public information regarding National Grid should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com.
About Glancy Prongay & Murray LLP
Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.
With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ('Seaport') a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that the first patient has been dosed in the Phase 2b BUOY-1 study of GlyphAllo™ SPT-300 or Glyph Allopregnanolone) in major depressive disorder (MDD) with or without anxious distress. GlyphAllo is a novel, 'Glyphed' oral prodrug of allopregnanolone, an endogenous molecule that has been shown to dampen stress. Allopregnanolone has been clinically validated in third-party trials as a rapidly acting antidepressant with anxiolytic effects, but its scope of clinical use was previously constrained by limitations that the Glyph™ platform is specifically designed to solve. GlyphAllo has the potential to be a first-in-class treatment for patients with MDD, including those with or without anxious distress. The full text of the announcement from Seaport is as follows: Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo ™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress BUOY-1 builds on successful Phase 1 and Phase 2a data with GlyphAllo – a novel oral prodrug of allopregnanolone and a potential first-in-class treatment for MDD Allopregnanolone has demonstrated rapid antidepressant and anxiolytic activity in clinical settings, but its clinical scope was previously constrained by limitations that Glyph™ is specifically designed to solve Boston, MA – July 17, 2025 – Seaport Therapeutics ('Seaport' or the 'Company'), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that the first patient has been dosed in the Phase 2b BUOY-1 study of GlyphAllo™ (SPT-300 or Glyph Allopregnanolone) in major depressive disorder (MDD) with or without anxious distress. GlyphAllo is a novel, 'Glyphed' oral prodrug of allopregnanolone, an endogenous molecule that has been shown to dampen stress. Allopregnanolone has been clinically validated in third-party trials as a rapidly acting antidepressant with anxiolytic effects, but its scope of clinical use was previously constrained by limitations that the Glyph™ platform is specifically designed to solve. GlyphAllo has the potential to be a first-in-class treatment for patients with MDD, including those with or without anxious distress. 'The initiation of BUOY-1 marks a significant milestone for Seaport's pipeline, bringing us closer to a potential new treatment for major depression, which impacts around 280 million people globally – nearly 60 percent of whom also experience anxious distress,' said Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics. 'This is an important step on our journey to deliver new treatments for patients living with depression, anxiety, and other neuropsychiatric conditions.' BUOY-1 is a global, randomized, double-blind, placebo-controlled study that will evaluate the efficacy, safety, and tolerability of GlyphAllo in adults with MDD, with or without anxious distress, a subtype of depression characterized by significant anxiety. The study is expected to enroll up to approximately 360 patients, randomized 1:1 to receive either GlyphAllo or placebo once-daily over a six-week treatment period. The primary endpoint of the study is the change from baseline at six weeks in the Hamilton Depression Rating Scale-17 (HAM-D-17), a gold-standard depression severity rating scale. Following the initial treatment period, eligible patients may enter an open-label extension phase, during which all participants will receive GlyphAllo for up to an additional six weeks. 'CNS clinical trials are inherently complex, and we are applying our team's extensive expertise to implement a high-quality study,' said Antony Loebel, M.D., Chief Medical Officer, President of Clinical Development at Seaport Therapeutics. 'We are confident that our rigorous clinical trial execution, including an emphasis on the quality of patient enrollment, will build on a proven mechanism and established clinical efficacy, to increase our likelihood of success in developing an effective treatment for patients with depression." The BUOY-1 study builds on a foundation of positive clinical data from Phase 1 and Phase 2a studies of GlyphAllo in healthy volunteers. In Phase 1, GlyphAllo demonstrated approximately nine times greater allopregnanolone exposure than that previously reported following oral dosing of allopregnanolone and reached similar exposures to the efficacious doses of IV-infused allopregnanolone. The two key measures used to determine allopregnanolone-associated brain activity, EEG beta frequency power and reduction in saccadic eye velocity, confirmed that GlyphAllo engaged with its target in a dose-dependent manner. The overall safety data, pharmacokinetics, and pharmacodynamic findings, along with non-clinical studies, support six-week dosing of GlyphAllo in BUOY-1. In a Phase 2a proof-of-concept study in healthy volunteers using the Trier Social Stress Test (TSST), a validated clinical model of anxiety, GlyphAllo significantly reduced the stress hormone salivary cortisol at all post-TSST timepoints compared to placebo, meeting the primary endpoint with a p-value of 0.0001 and demonstrating that GlyphAllo regulates hypothalamic-pituitary-adrenal axis reactivity to acute stress. GlyphAllo was generally well-tolerated, with adverse events that were mostly mild and transient. About the Glyph ™ Platform Glyph is Seaport's proprietary technology platform which uses the lymphatic system to enable and enhance the oral administration of drugs. With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism otherwise leading to low bioavailability and/or side effects, including liver enzyme elevations or hepatotoxicity. For each program, Seaport leverages its Glyph platform to create unique sets of prodrugs with differentiated profiles, including lymphatic transport and conversion characteristics, as potential candidates to advance into preclinical and clinical proof-of-concept studies. Seaport exclusively licensed this technology from Monash University based on the pioneering research of the Porter Research Group. Advanced initially at PureTech Health and now at Seaport, Glyph has been applied to create therapeutic candidates for the Company's pipeline resulting in new intellectual property, including composition of matter. The group and its collaborators have published research in Nature Metabolism, Frontiers in Pharmacology, Journal of Controlled Release and Molecular Pharmaceutics supporting the Glyph platform's capabilities. See Glyph in action here. About GlyphAllo™ (SPT-300 or Glyph Allopregnanolone) GlyphAllo (SPT-300 or Glyph Allopregnanolone), an oral prodrug of allopregnanolone, is in clinical stage development for the treatment of major depressive disorder (MDD) with or without anxious distress. Allopregnanolone, an endogenous molecule that has been shown to dampen stress, has antidepressant and anxiolytic activity and sleep-promoting effects but poor oral bioavailability due to substantial first-pass hepatic metabolism. Allopregnanolone was previously only approved as an intravenous infusion, which limited the scope of its clinical use. A synthetic analog of allopregnanolone was previously evaluated in MDD and showed promise but may not retain the activity, potency and the breadth of the natural biological response of endogenous allopregnanolone. In a Phase 1 clinical study, GlyphAllo demonstrated oral bioavailability, tolerability and γ-aminobutyric-acid type A (GABA A) receptor target engagement in healthy volunteers. In a Phase 2a clinical study, GlyphAllo demonstrated initial proof-of-concept in the Trier Social Stress Test, a validated clinical model of anxiety in healthy volunteers. GlyphAllo is currently being evaluated in the Phase 2b BUOY-1 study for MDD, with or without anxious distress. About Seaport Therapeutics Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and is guided by an extensive network of renowned scientists, clinicians, and key opinion leaders. For more information, please visit About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit or connect with us on X (formerly Twitter) @puretechh. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to Seaport's development plans for its pipeline of neuropsychiatric therapeutics based on the Glyph™ Platform, the potential of GlyphAllo™ and the Glyph™ platform, the design and expected safety and efficacy outcomes of the BUOY-1 study, the broader applicability of the platform, the addressable market for Seaport's product candidates, if approved, potential benefits to patients, and Seaport's and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
National Post
an hour ago
- National Post
Behavox Responds to Growing Demand for Alert Review Services as Compliance Teams Battle Backlogs and Resource Constraints
Article content LONDON — Behavox, the AI company that transforms data into insights that safeguard and enhance businesses, today announced continued momentum for its Alert Review Managed Services, reporting a 102% increase in client adoption over the past quarter. The surge in adoption reflects a growing industry need for scalable, experienced and vendor-agnostic compliance operations that can keep pace with mounting alert volumes and limited internal resources. Adoption spans 1st line reviewers and 2nd line supervisors, enabling a unified review across communications and trade data. Article content As compliance teams face record-high alert queues, consistent regulatory pressures, and staffing shortages, Behavox's managed service has emerged as a trusted solution for delivering consistent, audit-ready alert reviews – regardless of which surveillance platform a firm uses. Investment Banks, Asset Managers, Hedge funds and Private Equity firms are increasingly turning to Behavox Managed Services to scale alert coverage, meet compliance SLAs, and reduce operational risk. The service supports both communications and trade surveillance, providing surge resourcing, backlog clearance, and end-to-end adjudication workflows tailored to each client's policy and platform. Article content Article content 'Clients come to us when they realize their existing team can't scale fast enough,' said Michael Talbert, Head of Professional Services at Behavox. 'We're seeing firms add monitored employees or risk categories, and depending on the new requirements, their alert volumes might double overnight. That's when backlogs appear, analyst turnover spikes, and the quality of review becomes inconsistent. Behavox steps in to stabilize and scale operations fast, often within days.' Article content With onshore and nearshore review teams in the UK, EU, North America, and APAC, Behavox delivers a regionalized, secure, and audit-ready service led by experienced compliance professionals, not generic offshore staff. All analysts undergo certification aligned to Behavox's risk policy framework, and every deployment includes granular audit trails and privileged access controls. The model has been described by customers as a strategic advantage, not just a cost-saving tool. One global investment bank used Behavox to reduce daily alert review from eight hours to under 20 minutes – freeing internal resources for proactive risk analysis and investigations. Article content Behavox Alert Review Managed Services deliver three strategic advantages: Article content Comprehensive Surveillance Coverage: The only vendor providing unified managed services across both communication and trade surveillance alert review, with native language analysts and regional teams across the UK, EU, North America, and APAC to ensure contextual accuracy and policy alignment. Precision-Driven Workflows: Alerts are reviewed with precision – not just cleared – through layered adjudication models that include certified compliance professionals, SME oversight, and AI-augmented analysis. This ensures consistent quality whether handling backlogs, short-term surges, or long-term operational needs. Platform-Agnostic Delivery: Behavox Alert Review is available to all firms, regardless of existing systems. The service integrates seamlessly with both proprietary platforms and third-party lexicon-based surveillance systems – no Behavox software required. Article content Francois Suanez, Article content Head of SME at Behavox, added: 'A modern compliance operating model requires independence, specialization, and scale. Behavox offers firms all three. Our teams handle day-to-day alert review, while your internal staff can focus on forward-looking risk, regulator responses, or model validation. Best of all, Article content . We work with firms using legacy, lexicon-based surveillance systems, too.' Article content About Behavox: Article content Behavox is the leading provider of AI-powered compliance and conduct surveillance solutions. The company's flagship product, the Behavox Intelligent Archive, enables regulated firms to capture, retain, and analyze communications and behavioral data across channels — empowering compliance, legal, and risk functions to reduce exposure, respond swiftly to regulators, and create a culture of integrity. Article content Article content Article content Contacts Article content Media Contact: Article content Article content Article content
National Post
an hour ago
- National Post
AECOM selected to design major track improvements for England's busiest passenger railway corridors
Article content All statements in this communication other than statements of historical fact are 'forward-looking statements' for purposes of federal and state securities laws, including any statements of the plans, strategies and objectives for future operations, profitability, strategic value creation, capital allocation strategy including stock repurchases, risk profile and investment strategies, and any statements regarding future economic conditions or performance, and the expected financial and operational results of AECOM. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Important factors that could cause our actual results, performance and achievements, or industry results to differ materially from estimates or projections contained in our forward-looking statements include, but are not limited to, the following: our business is cyclical and vulnerable to economic downturns and client spending reductions; potential government shutdowns, changes in administration or other funding directives and circumstances that may cause governmental agencies to modify, curtail or terminate our contracts; losses under fixed-price contracts; limited control over operations that run through our joint venture entities; liability for misconduct by our employees or consultants; changes in government laws, regulations and policies, including failure to comply with laws or regulations applicable to our business; maintaining adequate surety and financial capacity; potential high leverage and inability to service our debt and guarantees; ability to continue payment of dividends; exposure to political and economic risks in different countries, including tariffs and trade policies, geopolitical events, and conflicts; inflation, currency exchange rates and interest rate fluctuations; changes in capital markets and stock market volatility; retaining and recruiting key technical and management personnel; legal claims and litigation; inadequate insurance coverage; environmental law compliance and adequate nuclear indemnification; unexpected adjustments and cancellations related to our backlog; partners and third parties who may fail to satisfy their legal obligations; managing pension costs; AECOM Capital real estate development projects; cybersecurity issues, IT outages and data privacy; risks associated with the benefits and costs of the sale of our Management Services and self-perform at-risk civil infrastructure, power construction and oil and gas businesses, including the risk that any purchase adjustments from those transactions could be unfavorable and result in any future proceeds owed to us as part of the transactions could be lower than we expect; as well as other additional risks and factors that could cause actual results to differ materially from our forward-looking statements set forth in our reports filed with the Securities and Exchange Commission. Any forward-looking statements are made as of the date hereof. We do not intend, and undertake no obligation, to update any forward-looking statement.
